STOCK TITAN

[8-K] KALTURA INC Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Kaltura, Inc. announced that John Doherty, its Chief Financial Officer, will resign effective December 5, 2025 to become CFO at a medical technology company. He will continue as CFO through the Separation Date and then serve as an advisor through March 31, 2026 to assist the transition. The company engaged an external search firm to identify a successor.

As part of the departure, Doherty will remain on base pay and benefits through the Separation Date and continue to receive equity vesting per his offer letter. He is eligible for a fixed portion of his 2025 annual cash bonus of $150,000, payable with other executives, and will receive a consultancy fee of $10,000 per month from the Separation Date through March 31, 2026. The filing also reaffirms the company’s third-quarter financial guidance previously disclosed on August 7, 2025.

Kaltura, Inc. ha annunciato che John Doherty, il suo Chief Financial Officer, rassegnerà le dimissioni con effetto dal 5 dicembre 2025 per diventare CFO di una società di tecnologia medica. Rimarrà CFO fino alla Data di Separazione e poi fungerà da consulente fino al 31 marzo 2026 per assistere la transizione. L'azienda ha incaricato una società di ricerca esterna per identificare un successore. Come parte della sua uscita, Doherty continuerà a ricevere lo stipendio base e i benefit fino alla Data di Separazione e continuerà a beneficiare del vesting delle azioni conformemente alla sua lettera di offerta. È idoneo a una quota fissa del suo bonus annuale 2025 di $150,000, pagata insieme agli altri dirigenti, e riceverà una diaria di consulenza di $10,000 al mese dalla Data di Separazione fino al 31 marzo 2026. La documentazione riconferma inoltre le previsioni finanziarie per il terzo trimestre già rese note il 7 agosto 2025.
Kaltura, Inc. anunció que John Doherty, su Director Ejecutivo Financiero, renunciará con efecto a partir del 5 de diciembre de 2025 para convertirse en CFO de una empresa de tecnología médica. Continuará como CFO hasta la Fecha de Separación y luego ejercerá como asesor hasta el 31 de marzo de 2026 para ayudar en la transición. La empresa contrató a una firma de búsqueda externa para identificar a un sucesor. Como parte de la salida, Doherty mantendrá su salario base y beneficios hasta la Fecha de Separación y continuará recibiendo la consolidación de acciones según su carta de oferta. Es elegible para una parte fija de su bonificación anual 2025 de $150,000, pagadera junto con los otros ejecutivos, y recibirá una tarifa de consultoría de $10,000 por mes desde la Fecha de Separación hasta el 31 de marzo de 2026. La presentación/archivo también reafirma la orientación financiera del tercer trimestre previamente divulgada el 7 de agosto de 2025.
Kaltura, Inc.은 최고재무책임자(CFO)인 John Doherty가 2025년 12월 5일부로 사임하고 의료 기술 기업의 CFO가 될 것이라고 발표했습니다. 그는 Separation Date까지 CFO로 남아 있고, 전환을 돕기 위해 2026년 3월 31일까지 고문으로 활동할 예정입니다. 회사는 후임자를 찾기 위해 외부 검색 회사를 고용했습니다. 퇴임의 일환으로 Doherty는 Separation Date까지 기본급과 혜택을 유지하고, 제안서에 따른 주식 vesting도 계속 받을 것입니다. 그는 $150,000의 2025년 연간 현금 보너스의 고정 부분에 자격이 있으며, 다른 경영진과 함께 지급되며 Separation Date부터 2026년 3월 31일까지 매달 $10,000의 컨설턴시 수수료를 받게 됩니다. 제출 서류는 또한 2025년 8월 7일에 이미 공개된 제3분기 재무 가이드라인을 재확인합니다.
Kaltura, Inc. a annoncé que John Doherty, son directeur financier, démissionnerait avec effet au 5 décembre 2025 pour devenir CFO d'une société de technologie médicale. Il restera CFO jusqu'à la Date de Séparation et exercera ensuite en tant que conseiller jusqu'au 31 mars 2026 afin d'aider à la transition. L'entreprise a fait appel à une firme de recherche externe pour identifier un successeur. Dans le cadre du départ, Doherty restera sur le salaire de base et les avantages jusqu'à la Date de Séparation et continuera de bénéficier de l'acquisition d'actions selon sa lettre d'offre. Il est éligible à une partie fixe de sa prime annuelle 2025 de $150,000, payée avec les autres dirigeants, et recevra des frais de conseil de $10,000 par mois à partir de la Date de Séparation jusqu'au 31 mars 2026. Le dépôt déclare également que les orientations financières du troisième trimestre précédemment divulguées le 7 août 2025 restent en vigueur.
Kaltura, Inc. gab bekannt, dass John Doherty, sein Chief Financial Officer, mit Wirkung vom 5. Dezember 2025 zurücktreten wird, um CFO bei einem Medizintechnikunternehmen zu werden. Er bleibt bis zum Separation Date CFO und wird danach bis zum 31. März 2026 als Berater tätig sein, um den Übergang zu unterstützen. Das Unternehmen hat eine externe Suchfirma beauftragt, einen Nachfolger zu finden. Im Rahmen des Abgangs wird Doherty bis zum Separation Date sein Grundgehalt und seine Benefits erhalten und erhält weiterhin die Aktienvesting gemäß seinem Angebotsschreiben. Er ist berechtigt für einen festen Anteil seines Jahresbonus 2025 in Höhe von $150,000, zahlbar zusammen mit den anderen Führungskräften, und erhält ab Separation Date bis zum 31. März 2026 eine Beratungspauschale von $10,000 pro Monat. Die Einreichung bestätigt auch die zuvor am 7. August 2025 offengelegte Guidance für das dritte Quartal.
أعلنت Kaltura, Inc. أن جون دوهيرتي، مديرها المالي، سيتنحى عن منصبه اعتباراً من 5 ديسمبر 2025 ليصبح المدير المالي لشركة تكنولوجيا طبية. سيبقى كمدير مالي حتى تاريخ الانفصال ثم يعمل كمستشار حتى 31 مارس 2026 للمساعدة في الانتقال. استأجمت الشركة شركة بحث خارجية لتحديد خلف له. كجزء من المغادرة، سيظل دوهيرتي على راتبه الأساسي ومزاياه حتى تاريخ الانفصال وسيستمر في رؤية vesting الأسهم وفقاً لخطاب عرضه. وهو مؤهل للحصول على جزء ثابت من مكافأته السنوية لعام 2025 البالغ $150,000، والمدفوع مع باقي التنفيذيين، وسيتلقى رسم استشارة قدره $10,000 شهرياً من تاريخ الانفصال حتى 31 مارس 2026. كما تؤكد الملفات أيضًا على توجيهات الشركة للربع الثالث التي أعلنت سابقاً في 7 أغسطس 2025.
Kaltura, Inc.宣布,首席财务官John Doherty将于2025年12月5日辞职,去往一家医疗技术公司担任CFO。他将一直担任CFO直至分离日期,并在2026年3月31日前作为顾问,以协助过渡。公司已聘请外部猎头公司来确定继任者。 在离职过程中,Doherty将在分离日期前保持基础工资和福利,并按照他的任职信继续获得股票归属。他有资格获得其2025年年度现金奖金的固定部分,金额为$150,000,与其他高管一同发放,并将从分离日期起到2026年3月31日每月收到一笔$10,000的咨询费。提交文件还重新确认了此前在2025年8月7日披露的第三季度财务指引。
Positive
  • Orderly transition: CFO remains in role until December 5, 2025 and will advise through March 31, 2026
  • Continuity measures: external search firm retained to identify a successor
  • Financial guidance: company reaffirmed Q3 2025 guidance disclosed on August 7, 2025
Negative
  • Leadership change: departure of the principal financial and accounting officer may create short-term execution risk
  • Additional cash expense: consultancy fees of $10,000 per month and a fixed $150,000 bonus component increase near-term cash outflows

Insights

Good governance steps reduce near-term disruption risk.

The CFO departure is orderly: the executive will remain in role until December 5, 2025 and provide advisory support through March 31, 2026, which helps preserve continuity for financial reporting and investor communications. The company also retained an external search firm to recruit a replacement.

Key dependencies include successful recruitment and the company’s ability to maintain its third-quarter guidance through the transition; monitor hiring progress and any changes to public disclosures over the next 3–6 months.

Separation terms are modest and time‑limited.

The package includes a $150,000 fixed 2025 bonus component and a $10,000 monthly consultancy fee through March 31, 2026, with continued equity vesting through the Separation Date. These amounts are explicit and bounded in time, limiting recurring expense exposure.

Watch for the filing of the full separation and consultancy agreements (Exhibits 10.1 and 10.2) and any incremental disclosure on severance, acceleration, or replacement hiring within the next quarter.

Kaltura, Inc. ha annunciato che John Doherty, il suo Chief Financial Officer, rassegnerà le dimissioni con effetto dal 5 dicembre 2025 per diventare CFO di una società di tecnologia medica. Rimarrà CFO fino alla Data di Separazione e poi fungerà da consulente fino al 31 marzo 2026 per assistere la transizione. L'azienda ha incaricato una società di ricerca esterna per identificare un successore. Come parte della sua uscita, Doherty continuerà a ricevere lo stipendio base e i benefit fino alla Data di Separazione e continuerà a beneficiare del vesting delle azioni conformemente alla sua lettera di offerta. È idoneo a una quota fissa del suo bonus annuale 2025 di $150,000, pagata insieme agli altri dirigenti, e riceverà una diaria di consulenza di $10,000 al mese dalla Data di Separazione fino al 31 marzo 2026. La documentazione riconferma inoltre le previsioni finanziarie per il terzo trimestre già rese note il 7 agosto 2025.
Kaltura, Inc. anunció que John Doherty, su Director Ejecutivo Financiero, renunciará con efecto a partir del 5 de diciembre de 2025 para convertirse en CFO de una empresa de tecnología médica. Continuará como CFO hasta la Fecha de Separación y luego ejercerá como asesor hasta el 31 de marzo de 2026 para ayudar en la transición. La empresa contrató a una firma de búsqueda externa para identificar a un sucesor. Como parte de la salida, Doherty mantendrá su salario base y beneficios hasta la Fecha de Separación y continuará recibiendo la consolidación de acciones según su carta de oferta. Es elegible para una parte fija de su bonificación anual 2025 de $150,000, pagadera junto con los otros ejecutivos, y recibirá una tarifa de consultoría de $10,000 por mes desde la Fecha de Separación hasta el 31 de marzo de 2026. La presentación/archivo también reafirma la orientación financiera del tercer trimestre previamente divulgada el 7 de agosto de 2025.
Kaltura, Inc.은 최고재무책임자(CFO)인 John Doherty가 2025년 12월 5일부로 사임하고 의료 기술 기업의 CFO가 될 것이라고 발표했습니다. 그는 Separation Date까지 CFO로 남아 있고, 전환을 돕기 위해 2026년 3월 31일까지 고문으로 활동할 예정입니다. 회사는 후임자를 찾기 위해 외부 검색 회사를 고용했습니다. 퇴임의 일환으로 Doherty는 Separation Date까지 기본급과 혜택을 유지하고, 제안서에 따른 주식 vesting도 계속 받을 것입니다. 그는 $150,000의 2025년 연간 현금 보너스의 고정 부분에 자격이 있으며, 다른 경영진과 함께 지급되며 Separation Date부터 2026년 3월 31일까지 매달 $10,000의 컨설턴시 수수료를 받게 됩니다. 제출 서류는 또한 2025년 8월 7일에 이미 공개된 제3분기 재무 가이드라인을 재확인합니다.
Kaltura, Inc. a annoncé que John Doherty, son directeur financier, démissionnerait avec effet au 5 décembre 2025 pour devenir CFO d'une société de technologie médicale. Il restera CFO jusqu'à la Date de Séparation et exercera ensuite en tant que conseiller jusqu'au 31 mars 2026 afin d'aider à la transition. L'entreprise a fait appel à une firme de recherche externe pour identifier un successeur. Dans le cadre du départ, Doherty restera sur le salaire de base et les avantages jusqu'à la Date de Séparation et continuera de bénéficier de l'acquisition d'actions selon sa lettre d'offre. Il est éligible à une partie fixe de sa prime annuelle 2025 de $150,000, payée avec les autres dirigeants, et recevra des frais de conseil de $10,000 par mois à partir de la Date de Séparation jusqu'au 31 mars 2026. Le dépôt déclare également que les orientations financières du troisième trimestre précédemment divulguées le 7 août 2025 restent en vigueur.
Kaltura, Inc. gab bekannt, dass John Doherty, sein Chief Financial Officer, mit Wirkung vom 5. Dezember 2025 zurücktreten wird, um CFO bei einem Medizintechnikunternehmen zu werden. Er bleibt bis zum Separation Date CFO und wird danach bis zum 31. März 2026 als Berater tätig sein, um den Übergang zu unterstützen. Das Unternehmen hat eine externe Suchfirma beauftragt, einen Nachfolger zu finden. Im Rahmen des Abgangs wird Doherty bis zum Separation Date sein Grundgehalt und seine Benefits erhalten und erhält weiterhin die Aktienvesting gemäß seinem Angebotsschreiben. Er ist berechtigt für einen festen Anteil seines Jahresbonus 2025 in Höhe von $150,000, zahlbar zusammen mit den anderen Führungskräften, und erhält ab Separation Date bis zum 31. März 2026 eine Beratungspauschale von $10,000 pro Monat. Die Einreichung bestätigt auch die zuvor am 7. August 2025 offengelegte Guidance für das dritte Quartal.
0001432133false00014321332025-10-062025-10-06

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 6, 2025
Kaltura, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware
001-40644
20-8128326
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
860 Broadway
3rd Floor
New York, New York 10003
(Address of Principal Executive Offices) (Zip Code)

(646) 290-5445
(Registrant’s telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbols
Name of each exchange
on which registered
Common stock, par value $0.0001 per share
KLTR
The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.





Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 6, 2025, John Doherty, Chief Financial Officer of Kaltura, Inc. (“Kaltura” or the “Company”), notified the Company of his intention to resign from this position, effective December 5, 2025 (the “Separation Date”), to take on a chief financial officer role at a medical technology company. As of the Separation Date, Mr. Doherty will also cease serving as the Company’s principal financial and accounting officer.

The Company has retained an external search firm to identify successor candidates for the Chief Financial Officer position. Additionally, Mr. Doherty has agreed to serve as an advisor to the Company through March 31, 2026, to help facilitate a smooth transition.

In connection with Mr. Doherty’s separation from the Company, the Company has entered into the following agreements with Mr. Doherty: (i) a separation letter agreement, dated October 6, 2025, pursuant to which Mr. Doherty shall continue to serve as Chief Financial Officer until the Separation Date, during which time he will continue to receive his base salary and benefits, including continued vesting of his outstanding equity awards, in accordance with his offer letter with the Company (the “Separation Agreement”), as well as that Mr. Doherty shall be eligible to receive a portion of his annual cash bonus under the 2025 Executive Compensation Plan at a fixed amount of $150,000, which shall be paid concurrently with the payment of such bonus to the other executives of the Company; and (ii) a consultancy agreement, dated October 6, 2025 (the “Consultancy Agreement”), pursuant to which in consideration for Mr. Doherty’s provision of professional consultancy services in connection with the Company’s financial and accounting activities and preparation of its financial public disclosures, Mr. Doherty shall receive a consultancy fee of $10,000 per month, from the Separation Date through March 31, 2026.

The foregoing summary of the Separation Agreement and Consultancy Agreement is not complete and is qualified in its entirety by reference to the complete text of those agreements, copies of which are filed as Exhibit 10.1 and Exhibit 10.2, respectively, to this Current Report on Form 8-K and incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

The Company is reaffirming its financial guidance for the third quarter, as provided in the Company’s financial results press release for the second quarter of 2025, dated August 7, 2025.

The information furnished under this Item 7.01 of this Current Report on Form 8-K shall not be deemed to be “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of such section, nor shall such information be deemed to be incorporated by reference in any previous or subsequent filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of the general incorporation language in such filings, except as expressly incorporated by specific reference in such filing.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including but not limited to, statements regarding the expected Chief Financial Officer transition and the Company’s third quarter financial guidance. Any forward-looking statements contained herein are based on our historical performance and our current plans, estimates and expectations and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent our expectations as of the date of this Current Report on Form 8-K. Subsequent events may cause these expectations to change, and we disclaim any obligation to update the forward-looking statements in the future, except as required by law. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from our current expectations. Important factors that could cause actual results to differ materially from those anticipated in our forward-looking statements include, but are not limited to, the risks under the caption “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”), as such factors may be updated from time to time in our other filings with the SEC, including in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, which are accessible on the SEC’s website at www.sec.gov and the Investor Relations page of our website at investors.kaltura.com.




Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.

Exhibit No.Description
10.1
Separation Agreement with Mr. John Doherty, dated October 6, 2025.
10.2
Consultancy Agreement with Mr. John Doherty, dated October 6, 2025.
99.1
Press Release dated October 6, 2025
eCo
104Cover Page Interactive Data File (embedded within the Inline XBRL document)




SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

KALTURA, INC.
By:/s/ Zvi Maayan
Name:Zvi Maayan
Title:General Counsel and Corporate Secretary

Date: October 6, 2025





FAQ

What did Kaltura (KLTR) announce about its CFO?

Kaltura announced that John Doherty will resign as CFO effective December 5, 2025 and will serve as an advisor through March 31, 2026.

Will John Doherty receive any separation payments from KLTR?

Yes. He is eligible for a fixed portion of his 2025 cash bonus of $150,000 and will receive a consultancy fee of $10,000 per month from the Separation Date through March 31, 2026.

Is Kaltura changing its financial guidance after the CFO departure?

No. The company reaffirmed its third-quarter 2025 financial guidance previously provided in its August 7, 2025 press release.

How is Kaltura handling the CFO replacement?

Kaltura has retained an external search firm to identify successor candidates for the CFO position.

Where can I find the full separation and consultancy agreements?

The filing states that the complete agreements are filed as Exhibit 10.1 and Exhibit 10.2 to the Current Report and are incorporated by reference.
KALTURA INC

NASDAQ:KLTR

KLTR Rankings

KLTR Latest News

KLTR Latest SEC Filings

KLTR Stock Data

231.74M
98.27M
36.39%
42.58%
0.65%
Software - Application
Services-prepackaged Software
Link
United States
NEW YORK